Chemomab Therapeutics

1. Chemomab/Scipher merger filing2H 2026Chemomab/Scipher merger filing, 2H 2026, material
2. Nebokitug RA IND filing2H 2026Nebokitug RA IND filing, 2H 2026, notable
3. Volixibat PSC NDA filing2H 2026Volixibat PSC NDA filing, 2H 2026, notable
4. Chemomab/Scipher merger litigation ruling4Q 2026Chemomab/Scipher merger litigation ruling, 4Q 2026, notable
5. Nebokitug RA corporate update1H 2027Nebokitug RA corporate update, 1H 2027, routine
6. Chemomab guidance update1Q 2027Chemomab guidance update, 1Q 2027, routine
7. Chemomab/Scipher merger strategic reviewMar 31, 2027Chemomab/Scipher merger strategic review, Mar 31, 2027, notable
8. Nebokitug RA enrollment done2H 2027Nebokitug RA enrollment done, 2H 2027, routine
9. Nebokitug RA Ph2 topline1H 2028Nebokitug RA Ph2 topline, 1H 2028, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.